{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:13:37Z","timestamp":1789773217317,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01235-8","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T22:01:47Z","timestamp":1721685707000},"page":"2209-2221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Filipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duarte","family":"Flor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aureliu","family":"Rosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Claro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Vilarinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o Paiva","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"publisher","unstructured":"Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol [Internet]. 2023;151(5):1145\u201354. Available from: https:\/\/doi.org\/10.1016\/j.jaci.2022.10.023","DOI":"10.1016\/j.jaci.2022.10.023"},{"key":"1235_CR2","doi-asserted-by":"crossref","unstructured":"Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8).","DOI":"10.3390\/ijms22084130"},{"key":"1235_CR3","doi-asserted-by":"publisher","unstructured":"Torres T, Ferreira EO, Gon\u00e7alo M, Mendes-bastos P. Update on Atopic Dermatitis A Dermatite At\u00f3pica em Revis\u00e3o. Orden Dos M\u00e9dicos [Internet]. 2019;32(9):606\u201313. Available from: https:\/\/doi.org\/10.20344\/amp.11963","DOI":"10.20344\/amp.11963"},{"issue":"6","key":"1235_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/jdv.17981","volume":"36","author":"N Neagu","year":"2022","unstructured":"Neagu N, Dianzani C, Avallone G, Dell\u2019Aquila C, Morariu SH, Zalaudek I, et\u00a0al. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review. J Eur Acad Dermatology Venereol. 2022;36(6):820\u201335.","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"1235_CR5","doi-asserted-by":"publisher","unstructured":"Gooderham MJ, Hong HC ho, Eshtiaghi P, Papp KA. Dupilumab A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3):S28\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.022","DOI":"10.1016\/j.jaad.2017.12.022"},{"issue":"6","key":"1235_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/12034754221130969","volume":"26","author":"F Koskeridis","year":"2022","unstructured":"Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis. J Cutan Med Surg. 2022;26(6):613\u201321.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"1235_CR7","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1080\/09546634.2022.2035309","volume":"33","author":"T Torres","year":"2022","unstructured":"Torres T, Paiva-Lopes MJ, Gon\u00e7alo M, Claro C, Oliveira M, Gomes J, et\u00a0al. Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study. J Dermatolog Treat. 2022;33(5):2554\u20139. https:\/\/doi.org\/10.1080\/09546634.2022.2035309.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1235_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/exd.14786","volume":"32","author":"M Miniotti","year":"2023","unstructured":"Miniotti M, Ribero S, Mastorino L, Ortoncelli M, Gelato F, Bailon M, et\u00a0al. Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with dupilumab: data up to 3 years. Exp Dermatol. 2023;32(6):852\u20138.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1235_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, et\u00a0al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408. https:\/\/doi.org\/10.1007\/s40257-022-00685-0.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1235_CR10","doi-asserted-by":"publisher","first-page":"T150","DOI":"10.1016\/j.ad.2023.11.004","volume":"115","author":"A Mart\u00ednez-Dom\u00e9nech","year":"2024","unstructured":"Mart\u00ednez-Dom\u00e9nech A, Zaragoza-Ninet V, Esteve-Mart\u00ednez A, Garc\u00eda-Rabasco A, S\u00e1nchez-Carazo JL, P\u00e9rez-Ferriols A. Efficacy and safety of dupilumab for the treatment of severe atopic dermatitis in clinical practice: a single center experience. Actas Dermosifiliogr. 2024;115(2):T150\u20138.","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"1235_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/00015555-3751","volume":"101","author":"M De Bruin-Weller","year":"2021","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et\u00a0al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):1\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1235_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2023.01.053","volume":"89","author":"J Yeung","year":"2023","unstructured":"Yeung J, Gooderham MJ, Hong HCH, Lynde C, Prajapati VH, Lansang P, et\u00a0al. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: a Canadian perspective. J Am Acad Dermatol. 2023;89(2):372\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2023.01.053.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1235_CR13","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1111\/1346-8138.17017","volume":"51","author":"DH Kang","year":"2024","unstructured":"Kang DH, Kwon SH, Lew BL. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: a real-world retrospective study. J Dermatol. 2024;51(3):e63\u20135.","journal-title":"J Dermatol"},{"issue":"6","key":"1235_CR14","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/jdv.18889","volume":"37","author":"E Pezzolo","year":"2023","unstructured":"Pezzolo E, Rossi MT, Caroppo F, Bianchelli T, Belloni Fortina A, Giacchetti A, et\u00a0al. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: a real-world prospective cohort study. J Eur Acad Dermatol Venereol. 2023;37(6):e757\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1235_CR15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","volume":"158","author":"LS Spekhorst","year":"2022","unstructured":"Spekhorst LS, De Graaf M, Zuithoff NPA, Van Den Reek JMPA, Kamsteeg M, Boesjes CM, et\u00a0al. Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice bioday registry. JAMA Dermatol. 2022;158(9):1048\u201356.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1235_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139\u201347. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.051.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1235_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/jdv.19126","volume":"37","author":"CM Olesen","year":"2023","unstructured":"Olesen CM, Halling AS. Conjunctivitis in atopic dermatitis patients treated with dupilumab\u2014worsening of pre-existing disease or de novo development? J Eur Acad Dermatol Venereol. 2023;37(7):1258\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1235_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/cea.14461","volume":"54","author":"R Achten","year":"2024","unstructured":"Achten R, Thijs J, van der Wal M, van Luijk C, Bakker D, Knol E, et\u00a0al. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy. Clin Exp Allergy. 2024;54:241\u201352.","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"1235_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2326480","volume":"23","author":"E Camela","year":"2024","unstructured":"Camela E, Giampetruzzi AR, De Pit\u00e0 O, Pallotta S, Russo F. Dupilumab in real-life settings: a review of adverse events and their pathogenesis. Expert Opin Drug Saf. 2024;23(4):1\u20139. https:\/\/doi.org\/10.1080\/14740338.2024.2326480.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1235_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/DER.0000000000000590","volume":"31","author":"J Jaros","year":"2020","unstructured":"Jaros J, Hendricks AJ, Shi VY, Lio PA. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31(3):169\u201377.","journal-title":"Dermatitis"},{"issue":"1","key":"1235_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","volume":"82","author":"RA Waldman","year":"2020","unstructured":"Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1235_CR22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347. https:\/\/doi.org\/10.1016\/j.jaad.2021.01.012.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1235_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","volume":"84","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States food and drug administration. J Am Acad Dermatol. 2021;84(4):1010\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1235_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1346-8138.16764","volume":"50","author":"M Napolitano","year":"2023","unstructured":"Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study. J Dermatol. 2023;50(7):880\u20137.","journal-title":"J Dermatol"},{"issue":"5","key":"1235_CR25","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/bjd.18031","volume":"181","author":"ZN Willsmore","year":"2019","unstructured":"Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, et\u00a0al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019;181(5):1068\u201370.","journal-title":"Br J Dermatol"},{"issue":"23","key":"1235_CR26","first-page":"00817","volume":"S0001\u20137310","author":"JM Alvarenga","year":"2023","unstructured":"Alvarenga JM, Maria L\u00e9 A, Torres T. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: a case report. Actas Dermosifiliogr. 2023;S0001\u20137310(23):00817\u201327.","journal-title":"Actas Dermosifiliogr"},{"key":"1235_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdin.2024.01.002","volume":"15","author":"D Metko","year":"2024","unstructured":"Metko D, Alkofide M, Abu-Hilal M. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. JAAD Int. 2024;15:5\u201311. https:\/\/doi.org\/10.1016\/j.jdin.2024.01.002.","journal-title":"JAAD Int."},{"key":"1235_CR28","first-page":"1","volume":"2024","author":"N Hong","year":"2023","unstructured":"Hong N, Park SY, Kook HD, Lee DH, Jung HJ, Park MY, et\u00a0al. Atopic dermatitis treated safely with dupilumab during pregnancy and lactation: a case series of four patients. Australas J Dermatol. 2023;2024:1\u20134.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"1235_CR29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2022.01.010","volume":"149","author":"G Balakirski","year":"2022","unstructured":"Balakirski G, Novak N. Atopic dermatitis and pregnancy. J Allergy Clin Immunol. 2022;149(4):1185\u201394. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1235_CR30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/jdv.18922","volume":"37","author":"DN Adam","year":"2023","unstructured":"Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et\u00a0al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 2023;37(6):1135\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1235_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19794","author":"G Avallone","year":"2024","unstructured":"Avallone G, Cavallo F, Tancredi A, Maronese CA, Bertello M, Fragh\u00ec A, et\u00a0al. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.19794.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01235-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:30:48Z","timestamp":1724077848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01235-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01235-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tiago Torres has received consultancy and\/or speaker's honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB. Maria Jo\u00e3o Cruz has received consultancy and\/or speaker's honoraria from AbbVie, Almirall, Beiersdorf, Eli Lilly, Galderma, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc.and Sanofi. Margarida Gon\u00e7alo was a speaker or advisor for Abbvie, Astrazeneca, Eli Lilly, Leo Pharma, Novartis, Pfizer, Sanofi and Takeda. Bruno Duarte has received speaker and\/or consultant fees from Sanofi, Eli-Lilly, Abbvie, Pfizer, Leo, Galderma and Janseen. Jo\u00e3o Alves has received consultancy and\/or speaker\u2019s honoraria from AbbVie and Galderma. Alberto Mota has received consultancy and\/or speaker's honoraria from AbbVie, Eli Lilly and Co., LEO Pharma, and Sanofi-Genzyme. Paulo Filipe, Jos\u00e9 Miguel Alvarenga, Gilberto Rosa, Duarte Flor, Jos\u00e9 Ramos, Diogo Sousa, Aureliu Rosca, C\u00e9sar Magalh\u00e3es, Cristina Claro, Joana Rocha, Catarina Vilarinho, Fernando Mota, and Maria Jo\u00e3o Paiva Lopes declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki initially published in 1964 on Ethical Principles for Medical Research Involving Human Subjects and after approval by the local ethical committees. Patients consent was exempted due to the retrospective nature of the study: the study protocol did not deviate from standard clinical practice, and data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}